Case Study
April 8, 2020

Tackling A Crisis Together

NanoMosaic is collaborating with Massachusetts General Hospital (MGH) in Boston, Mass. to deploy a new approach to treating COVID-19 patients using NanoMosaic’s “Tessera” system to potentially monitor and evaluate the effect of FDA-approved treatments and methodologies.

NanoMosaic’s technology platform, which employs nanoneedle-based detection technologies to facilitate ultra-sensitive, multiplexed protein detection over a wide dynamic range, may be used by MGH clinicians to analyze the effectiveness of currently approved medicines.

“We will explore the potential methods to track the effectiveness of the treatments by monitoring the COVID-19 specific antibodies of patients before and after administering the treatments; thus, tracking the prognostics of the infection and evaluate the effectiveness of our treatment,” said Dr. Zhongcong Xie, Henry K. Beecher Professor of Anaesthesia at Harvard Medical School, and an attending anesthesiologist at MGH.

Dr. Qimin Quan, Chief Scientific Officer at NanoMosaic, said the company’s Tessera platform employs the nanoneedle technology, allowing sensitive and multiplexed quantification of a panel of COVID-19 specific antibodies.

“An immunity test can provide deep insights for disease prognostics and also enable the monitoring of patient's immunity levels after they have recovered, which is a key issue for vaccination,” Dr. Quan said.

Hospitals presently lack the ability to quantify very low to high antibody levels. The Tessera system allows MGH clinicians to quickly get the tools they need to assess how effective treatments are for patients.

“Upon development of the test, NanoMosaic will work with the FDA towards a path for approval for widespread deployment to healthcare networks across the country,” said John Boyce, President and CEO of NanoMosaic and Co-Founder of Tiger Gene. “The dual capability of the Tessera platform to determine the effectiveness of treatment and the power to monitor patients' immunity levels will have a profound improvement on both healthcare as well as the economy.”

NanoMosaic At a Glance:

  • LLC
  • Founded 2017
  • Headquartered in Woburn, Mass.
  • 7 employees
  • Goodwin client since 2020